Isoprostane/FMD Study The Effect of Protein Kinase C (PKC) β Specific Inhibitor LY333531 on Oxidant Stress in Patients With Type 2 Diabetes Mellitus

Status:
Completed

Trial end date:
2005-07-01

Target enrollment:

Participant gender:

The purpose of this study is to determine whether ruboxistaurin can reduce blood vessel inflammation associated with diabetes.

Phase 1

Chromaderm, Inc.

Ruboxistaurin